Katsuo Usuda Yo Niida Shun Iwai Aika Funasaki Atsushi Sekimura Nozomu Motono Sohsuke Yamada Hidetaka Uramoto
10.3389/fonc.2020.00689
Front Oncol
2020 Jun 2;10:689.
immune checkpoint inhibitor (ici) lung cancer microsatellite instability (msi) programmed death ligand 1 (pd-l1) tumor mutation burden (tmb)
CC BY
https://pubmed.ncbi.nlm.nih.gov/32582526/
Case Reports
PMC7280536
32582526
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report
2020